Abstract
Type 2 diabetes mellitus (T2DM) is a progressive multisystem disease, and less than half the population with T2DM has achieved the recommended glycosylated haemoglobin A1c goal. We aim to present key points to consider when selecting pharmacotherapy for the management of T2DM. The selection of pharmacotherapy is discussed within the context of the underlying pathophysiology of T2DM, currently available treatment options highlighting newer agents and current clinical guidelines. Combination therapy regimens that target the multiple organ systems involved in the pathophysiology of T2DM can be developed based on the mechanism of action (MOA) of each class of agents. We compare the pathophysiology of T2DM with the MOA of the currently available non-insulin therapeutic options. Combination therapy that efficiently and effectively targets multiorgan correction with the least risk for serious adverse events, such as hypoglycaemia and drug interactions, is needed when initial treatment fails to achieve the desired clinical outcomes. Newer agents, now incorporated in treatment guidelines, increase the range of options available to the clinician.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.